J B Chemicals Pharmaceuticals to launch Molnupiravir 200 mg in India

J B Chemicals Pharmaceuticals to launch Molnupiravir 200 mg in India

January 01, 1970 5:30 IST | capital market
J B Chemicals Pharmaceuticals is set to launch Molnupiravir 200 mg for the Indian market Marketed under the brand name Molunamax it will soon be available all across the country in the next month for the treatment of mild COVID-19 Recently Molnupiravir received US FDA Emergency Use AuthorizationEUA for the Treatment of Mild to Moderate COVID-19 Molnupiravir should be administered as soon as possible after a diagnosis of COVID-19 has been made and within five days of symptom onset In India the CDSCO has recently recommended for grant of permission to manufacture and market Molnupiravir 200 mg capsule for restricted use under emergency situation in the country for treatment of patients above the age of 18 years diagnosed COVID-19 positive with SpO2 > 93Percentage and those who have a high risk of progression of the disease The recommended dose for Molnupiravir is 800 mg four 200 mg capsules taken orally every 12 hours for five days with or without food Completion of the full five-day treatment course is important to maximize viral clearance and may help in minimizing the transmission of SARS-CoV-2

FREE Benefits Worth 5,000



Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity